European Pharmaceutical Review
AUGUST 4, 2023
According to data and analytics company GlobalData , Boehringer Ingelheim’s Cyltezo has demonstrated the intersection of price and regulation in the biosimilars market. “Of This has developed following numerous adalimumab biosimilar offerings being brought to market. billion in 2022, a product that was launched in 2002.
STAT
FEBRUARY 13, 2023
Humira has been the world’s best-selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
AUGUST 1, 2023
The potential revenue replacing Humira has resulted in many adalimumab biosimilar offerings being brought forth (currently nine FDA-approved agents), and a rapidly overcrowded market. Against this backdrop, Cyltezo from Boehringer Ingelheim has shown the intersection of price and regulation in the biosimilar market, says GlobalData.
STAT
FEBRUARY 13, 2023
Humira has been the world’s best-selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita.
pharmaphorum
FEBRUARY 18, 2021
6 The stakes were extremely high, with annual costs of insulin reaching $736 per patient in 2013, up threefold since 2002. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. RESULT: As of 2002, 40% of PRILOSEC patients had switched to NEXIUM, which notched up sales of $3.9 billion in 2004.14
FDA Law Blog: Biosimilars
JUNE 11, 2023
Between 2002 and 2019, there were 768 products with pediatric labeling changes under BPCA and/or PREA. However, given FDA’s prior announced policy, it is somewhat surprising that only 16% of pediatric labeling changes pursuant to BPCA and/or PREA between 2002 and 2019 were conducted under both the BPCA and PREA.
PharmaShots
MARCH 29, 2023
Some companies accept the offered period and open doors to biological drugs or biosimilars. As of now, there are no the US FDA approved biosimilars available for Actemra. However, last August, Fresenius Kabi announced the US FDA's acceptance of its biosimilar BLA, bringing a potential candidate into the market before long.
Expert insights. Personalized for you.
75 
Let's personalize your content